228 related articles for article (PubMed ID: 15950742)
1. Adjuvant effect of Taenia crassiceps glycans against leishmanial antigens in mice infected with Leishmania mexicana.
Dissanayake S; Shahin A; Ameen AM
Mol Immunol; 2005 Aug; 42(12):1495-502. PubMed ID: 15950742
[TBL] [Abstract][Full Text] [Related]
2. Acute cysticercosis favours rapid and more severe lesions caused by Leishmania major and Leishmania mexicana infection, a role for alternatively activated macrophages.
Rodríguez-Sosa M; Rivera-Montoya I; Espinoza A; Romero-Grijalva M; López-Flores R; González J; Terrazas LI
Cell Immunol; 2006 Aug; 242(2):61-71. PubMed ID: 17118349
[TBL] [Abstract][Full Text] [Related]
3. [Determination of the specificity of seric IgA produced in response to antigens of Leishmania (Leishmania) mexicana in murine leishmaniasis].
Pérez-Aguilar MC; Hernández O; Maizo de Segnini Z; Rojas CH; Díaz S; Alarcón M; Goncalves L
Invest Clin; 2011 Sep; 52(3):216-29. PubMed ID: 21950193
[TBL] [Abstract][Full Text] [Related]
4. Leishmania amazonensis: humoral response to amastigote excreted-antigens in murine leishmaniasis.
Hernández-Chinea C
Exp Parasitol; 2007 Aug; 116(4):492-6. PubMed ID: 17349625
[TBL] [Abstract][Full Text] [Related]
5. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
[TBL] [Abstract][Full Text] [Related]
6. Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12/23p40.
Hernández MX; Barçante TA; Vilela L; Tafuri WL; Afonso LC; Vieira LQ
Immunol Lett; 2006 May; 105(1):38-47. PubMed ID: 16466810
[TBL] [Abstract][Full Text] [Related]
7. Aluminium phosphate potentiates the efficacy of DNA vaccines against Leishmania mexicana.
Rosado-Vallado M; Mut-Martin M; García-Miss Mdel R; Dumonteil E
Vaccine; 2005 Nov; 23(46-47):5372-9. PubMed ID: 16054271
[TBL] [Abstract][Full Text] [Related]
8. T-cell responses to immunodominant LACK antigen do not play a critical role in determining susceptibility of BALB/c mice to Leishmania mexicana.
Torrentera FA; Glaichenhaus N; Laman JD; Carlier Y
Infect Immun; 2001 Jan; 69(1):617-21. PubMed ID: 11119565
[TBL] [Abstract][Full Text] [Related]
9. CTL responses to Leishmania mexicana gp63-cDNA vaccine in a murine model.
Ali SA; Rezvan H; McArdle SE; Khodadadi A; Asteal FA; Rees RC
Parasite Immunol; 2009 Jul; 31(7):373-83. PubMed ID: 19527453
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of DNA vaccines encoding various antigens against Leishmania mexicana.
Dumonteil E; Andrade-Narvarez F; Escobedo-Ortegon J; Ramirez-Sierra MJ; Valencia-Pacheco G; Flores-Serrano A; Canto-Lara S; Arjona-Torres A
Dev Biol (Basel); 2000; 104():135-41. PubMed ID: 11713811
[TBL] [Abstract][Full Text] [Related]
11. Successful vaccination against Leishmania chagasi infection in BALB/c mice with freeze-thawed Leishmania antigen and Corynebacterium parvum.
Vilela Mde C; Gomes DC; Marques-da-Silva Ede A; Serafim TD; Afonso LC; Rezende SA
Acta Trop; 2007; 104(2-3):133-9. PubMed ID: 17919443
[TBL] [Abstract][Full Text] [Related]
12. Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis.
Oliveira-Freitas E; Casas CP; Borja-Cabrera GP; Santos FN; Nico D; Souza LO; Tinoco LW; da Silva BP; Palatnik M; Parente JP; Palatnik-de-Sousa CB
Vaccine; 2006 May; 24(18):3909-20. PubMed ID: 16556475
[TBL] [Abstract][Full Text] [Related]
13. Induction of interferon-gamma by Taenia crassiceps glycans and Lewis sugars in naive BALB/c spleen and peritoneal exudate cells.
Dissanayake S; Shahin A
Mol Immunol; 2007 Mar; 44(7):1623-30. PubMed ID: 17034862
[TBL] [Abstract][Full Text] [Related]
14. Vaccination of different strains of mice against cutaneous leishmaniosis: usefulness of membrane antigens encapsulated into liposomes by intraperitoneal and subcutaneous administration.
Lezama-Dávila CM
Arch Med Res; 1997; 28(1):47-53. PubMed ID: 9078587
[TBL] [Abstract][Full Text] [Related]
15. Genetic background influences immune responses and disease outcome of cutaneous L. mexicana infection in mice.
Rosas LE; Keiser T; Barbi J; Satoskar AA; Septer A; Kaczmarek J; Lezama-Davila CM; Satoskar AR
Int Immunol; 2005 Oct; 17(10):1347-57. PubMed ID: 16141242
[TBL] [Abstract][Full Text] [Related]
16. Intranasal vaccination with killed Leishmania amazonensis promastigotes antigen (LaAg) associated with CAF01 adjuvant induces partial protection in BALB/c mice challenged with Leishmania (infantum) chagasi.
Leal JM; Mosquini M; Covre LP; Stagmiller NP; Rodrigues RR; Christensen D; de Matos Guedes HL; Rossi-Bergmann B; Gomes DC
Parasitology; 2015 Nov; 142(13):1640-6. PubMed ID: 26394776
[TBL] [Abstract][Full Text] [Related]
17. Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes.
Russell DG; Alexander J
J Immunol; 1988 Feb; 140(4):1274-9. PubMed ID: 3257774
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant guided polarization of the immune humoral response against a protective multicomponent antigenic protein (Q) from Leishmania infantum. A CpG + Q mix protects Balb/c mice from infection.
Parody N; Soto M; Requena JM; Alonso C
Parasite Immunol; 2004; 26(6-7):283-93. PubMed ID: 15541032
[TBL] [Abstract][Full Text] [Related]
19. A trial of immunotherapy against Leishmania amazonensis infection in vitro and in vivo with Z-100, a polysaccharide obtained from Mycobacterium tuberculosis, alone or combined with meglumine antimoniate.
Barroso PA; Marco JD; Calvopina M; Kato H; Korenaga M; Hashiguchi Y
J Antimicrob Chemother; 2007 Jun; 59(6):1123-9. PubMed ID: 17439977
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of vaccination with a combination of Leishmania amastigote antigens and the lipid A-analogue ONO-4007 for immunoprophylaxis and immunotherapy against Leishmania amazonensis infection in a murine model of New World cutaneous leishmaniasis.
Calvopina M; Barroso PA; Marco JD; Korenaga M; Cooper PJ; Nonaka S; Hashiguchi Y
Vaccine; 2006 Jul; 24(27-28):5645-52. PubMed ID: 16621179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]